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Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is expressed on the membrane of B-lymphocytes and blocks
B cell receptor (BCR) signaling in EBV-transformed B-lymphocytes in vitro. The LMP2A amino-terminal domain, which is
essential for the LMP2A-mediated block of B cell signal transduction, contains eight tyrosine residues. Three of these
tyrosine residues (Y74, Y85, and Y112) have been demonstrated to be essential for the LMP2A-mediated block on protein
tyrosine phosphorylation, calcium mobilization, and induction of BZLF1 expression after BCR activation. To investigate the
importance of tyrosines at positions 60, 64, and 101 on B cell signaling, EBV recombinants were constructed containing a
tyrosine-to-phenylalanine point mutation at amino acid 60, 64, or 101 within LMP2A. Tyrosine phosphorylation, calcium
mobilization, and induction of BZLF1 expression were not affected by any of the tyrosine point mutations after BCR activation.
In addition, constitutive phosphorylation of LMP2A was unaffected by any of the tyrosine point mutations. These data indicate
that tyrosines 60, 64, and 101 are not essential for the LMP2A-mediated block of B cell signal transduction in transformed
cell lines. © 1999 Academic Press
v
l
L
p
d
u
y
1
E
n
L
r
i
r
o
1
p
a
n
t
w
(
a
p
w
P
P
t
hINTRODUCTION
Epstein–Barr virus (EBV) is a g-herpesvirus that
auses infectious mononucleosis in normal adolescents
nd is carried by a majority of the human population as
persistent asymptomatic infection. EBV has been etio-
ogically linked to a variety of hematopoetic diseases
uch as African Burkitt’s lymphoma, Hodgkin’s disease,
nd lymphoproliferative diseases in immunocompro-
ised individuals (Rickinson and Kieff, 1996). In addition,
BV is also associated with two epithelial pathologies:
asopharyngeal carcinoma and oral hairy leukoplakia
for a review, see Liebowitz, 1998).
B-lymphocytes are readily infected with EBV in vivo
nd in vitro. Primary human B-lymphocytes infected in
itro with EBV become immortalized, establishing lym-
hoblastoid cell lines (LCLs). These EBV-transformed
CLs contain the EBV episome and nine latent viral
ncoded proteins: six are nuclear proteins (EBNA1,
BNA2, EBNA3A, EBNA3B, EBNA3C, and EBNA-LP), and
hree are integral membrane proteins (LMP1, LMP2A,
nd LMP2B) (for reviews, see Kieff, 1996; Longnecker,
998). EBNA1 is required for episomal maintenance.
BNA2, EBNA3A, EBNA3C, EBNA-LP, and LMP1 have
een demonstrated to mediate EBV transformation in
1 Current address: Department of Plant and Microbial Biology, Uni-
ersity of California, Berkeley, CA 94701.
2 To whom reprint requests should be addressed at 303 E. Chicago
venue, Chicago, IL 60611. Fax: (312) 503-1339. E-mail: r-longnecker@lwu.edu.
485itro. EBNA3B, LMP2A, and LMP2B are dispensable for
ymphocyte transformation (for reviews, see Kieff, 1996;
ongnecker, 1998). However, of the latency expressed
roteins, only the EBNA1 and LMP2A messages are
etected in PCR analysis of B-lymphocytes from individ-
als harboring latent infections (Chen et al., 1995; Mi-
ashita et al., 1997; Qu and Rowe, 1992; Tierney et al.,
994). In addition, LMP2A can frequently be detected in
BV-related disorders such as nasopharyngeal carci-
oma and Hodgkin’s disease either by the presence of
MP2A-specific mRNA or by protein expression (for a
eview, see Liebowitz, 1998). Thus LMP2A may have
mportant roles in vivo for viral persistence and EBV-
elated diseases.
LMP2A localizes in patches on the plasma membrane
f latently infected B-lymphocytes. LMP2A contains a
19-amino-acid cytoplasmic amino-terminus, 12 hydro-
hobic transmembrane-spanning domains, and a 27-
mino-acid cytoplasmic carboxyl-terminal domain (Long-
ecker and Kieff, 1990) (Sample et al., 1989). This amino-
erminal domain includes eight tyrosine residues, 2 of
hich form an immunoreceptor tyrosine-based motif
ITAM) (Cambier, 1995; Reth, 1989). In addition, the
mino-terminal domain has been shown to be tyrosine
hosphorylated and necessary for LMP2A association
ith Src family protein tyrosine kinases (PTKs) and Syk
TK (Burkhardt et al., 1992; Longnecker et al., 1991).
hosphorylation of each tyrosine residue provides a po-
ential binding site for cellular proteins containing Src
omology 2 (SH2) domains. SH2 domains are noncata-ytic domains conserved among cytoplasmic signaling
0042-6822/99 $30.00
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486 SWART, FRUEHLING, AND LONGNECKERroteins and bind to phosphotyrosine motifs (for a re-
iew, see Mayer and Gupta, 1998). Previous studies have
emonstrated LMP2A phosphotyrosine motifs at posi-
ions 74/85 and 112 are required for the binding of Syk
nd Lyn, respectively (Fruehling and Longnecker, 1997;
ruehling et al., 1998).
In addition to the association of LMP2A with PTKs,
MP2A has dramatic effects on B cell signal transduc-
ion. In primary B-lymphocytes, activation of the B cell
eceptor (BCR) results in the up-regulation of protein
yrosine phosphorylation by recruiting and activating Src
amily PTKs, followed by the recruitment and activation of
ther kinases and phosphatases, the hydrolysis of phos-
holipids, activation of protein kinase C, mobilization of
ntracellular calcium, and activation of nuclear transcrip-
ion factors specific for transcribing BCR signal-specific
enes (for a review, see DeFranco, 1997). These signals
an also be activated in an EBV-negative B cell line,
JAB, but upon expression of LMP2A in these cells, B
ell signal transduction is blocked (Miller et al., 1993).
tudies using EBV-transformed LCLs (EBV1LMP2A1)
emonstrated as well a block in protein tyrosine phos-
horylation, calcium mobilization, and nuclear gene tran-
cription after BCR activation (Miller et al., 1994). BCR
ctivation also failed to activate cellular signaling pro-
eins such as Lyn, Syk, phosphatidylinositol 3-kinase,
hospholipase C-g2, Vav, mitogen-activated protein ki-
ase, and Shc in EBV1LMP2A1 LCLs (Miller et al.,
995). In contrast, LMP2A null mutant LCLs
EBV1LMP2A2) resulted in the restoration of B cell
ignaling upon BCR activation (Miller et al., 1995). These
esults indicated the importance of the amino-terminal
omain of LMP2A in mediating BCR signal transduction.
The importance of specific tyrosines within the amino-
erminal domain in blocking BCR signal transduction
as confirmed by the analysis of EBV-infected LCLs
ontaining a tyrosine (Y)-to-phenylalanine (F) point mu-
ation at either of the tyrosines within the LMP2A ITAM
74 or 85) and at amino acid position 112. Tyrosine phos-
horylation, calcium mobilization, and BZLF1 expression
ere no longer blocked in LCLs infected with either the
TAM or LMP2AY112F mutants (Fruehling and Long-
ecker, 1997; Fruehling et al., 1998). The LMP2A ITAM
as also found to bind and negatively regulate Syk
ctivity (Fruehling and Longnecker, 1997), whereas ty-
osine 112 was found to be essential for LMP2A phos-
horylation, PTK loading, and down-modulation of PTKs
ssociated with BCR-mediated signal transduction
Fruehling et al., 1998).
In this study, amino acids 60, 64, and 101 were mutated
rom tyrosine to phenylalanine and incorporated into the
iral genome to generate LCLs infected with LMP2AY60F,
MP2AY64F, or LMP2AY101F recombinant virus. LCLs from
ach tyrosine point mutant were then analyzed for the effect
f each mutant on LMP2A phosphorylation and the ability toransduce signals through the BCR. aRESULTS
ite-specific mutations of the amino-terminal domain
f LMP2A and generation of LMP2A mutant LCLs
PCR-mediated mutagenesis was used to create DNA
ragments containing point mutations within the LMP2A
mino-terminal domain. Each LMP2A tyrosine residue at
osition 60, 64, and 101 was changed into a phenylala-
ine residue (Fig. 1). The recombinant LMP2A constructs
ere verified by sequencing (data not shown) and then
ncorporated into the EBV viral genome using a previ-
usly described strategy (Longnecker et al., 1992, 1993).
ecombinant viruses were then used to infect purified
-lymphocytes in culture to generate EBV-infected LCLs
s previously described (Marchini et al., 1991). Cultured
CLs were screened by PCR to identify the presence of
ecombinant LMP2A within the infecting EBV genome
data not shown). To determine the presence of each
pecific LMP2A tyrosine mutation, Southern blots were
erformed using the unique restriction enzyme site in-
orporated adjacent to each LMP2A point mutation (data
ot shown). Multiple LCLs were transformed with EBV
ontaining each of the tyrosine LMP2A point mutants. To
erify each EBV recombinant LCL contained the tyrosine-
o-phenylalanine point mutation at position 60, 64, or 101,
wo LCLs for each point mutant were sequenced for the
resence of the mutation. In all cases, the presence of
he mutation was confirmed, as expected (data not
hown). In addition, the silent nucleotide changes re-
uired for the addition of each new restriction en-
yme site were observed. These EBV1LMP2AY60F,
BV1LMP2AY64F, and LMP2AY101F LCLs are charac-
erized in this study.
MP2A protein expression in EBV1LMP2AY60F,
BV1LMP2AY64F, and EBV1LMP2AY101F LCLs
LMP2A expression was confirmed by immunoblots
sing the LMP2A-specific monoclonal antibody 14B7.
igure 2 contains representative data for LCLs contain-
ng each LMP2A tyrosine point mutation. LMP2A expres-
ion is evident in the EBV1LMP2A1 lane, whereas no
MP2A was detected in the EBV1LMP2A2 negative
ontrol lane, as expected. LMP2A expression in the
epresentative LCLs containing the LMP2AY60F,
MP2AY64F, or LMP2AY101F mutant was similar to
MP2A expression in the EBV1LMP2A1 LCL. Although
ome variation in LMP2A expression is apparent in Fig.
, four LCLs for each mutant were tested, and this dif-
erence was not significant. This disparity is likely due to
xperimental variation and variation between differ-
nt cell lines. To confirm LMP2A expression and to
erify subcellular localization of LMP2A, indirect
mmunofluorescence was performed using anti-LMP2A
ntibody 8C3. Representative LCLs containing each
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487EPSTEIN–BARR VIRUS LMP2A TYROSINES 60, 64, AND 101MP2A tyrosine point mutation were used in immunoflu-
rescence studies (Fig. 3). The EBV1LMP2A1 LCL (D)
howed a bright punctate staining typical of previously
hown LMP2A immunofluorescence, whereas the
FIG. 1. Tyrosine-to-phenylalanine point mutations in the LMP2A amino
omain is shown with each tyrosine indicated by an arrow. The signific
3 and 31 were shown to be nonessential (N) (Fruehling et al., 1996)
hereas, tyrosines 74, 85, and 112 are essential (E) (Fruehling and Lon
5 bind the Syk PTK (Fruehling and Longnecker, 1997) and tyrosine 112 b
0, 64, and 101 on LMP2A in vitro function, each tyrosine was mutated
o allow for identification of LCLs containing the LMP2A point mutation
equence.
FIG. 2. Expression of LMP2A in EBV1LMP2A1, EBV1LMP2A2, and
MP2A point mutant LCLs. The EBV1LMP2A1 LCL lane demonstrates
he wild-type LMP2A size (54 kDa). LMP2AY60F, LMP2AY64F, and
MP2AY101F LCLs depict a similar size band at relatively the same level
f expression. The slight variation seen in LMP2A expression is likely due
o variation in different cell lines. The EBV1LMP2A2 LCL lane, as ex-
ected, does not contain an LMP2A band. Triton X-100 lysates from
CLs (3 3 106) containing EBV1LMP2AY60F, EBV1LMP2AY64F,
BV1LMP2AY101F, EBV1LMP2A2, and EBV1LMP2A1 were separated
y electrophoresis through 9% SDS–PAGE and transferred to Immobilon.
embranes were blocked in 4% milk, immunoblotted with anti-LMP2A
ntibodies (14B7), incubated with HRP-conjugated rat Ig F(ab9)2 antibody,
nd detected by ECL. Protein standards are indicated at the left in kilo-Yaltons.BV1LMP2A2 LCL (E) depicted a dull background fluo-
escence without any punctate staining. EBV1LMP2AY60F
A), EBV1LMP2AY64F (B), and EBV1LMP2AY101F (C)
CLs all demonstrated a similar bright punctate fluores-
ence as shown in the EBV1LMP2A1 LCL (D) indicative
f LMP2A staining (Longnecker and Kieff, 1990).Thus the
utation of tyrosines 60, 64, and 101 does not alter the
xpression or localization of LMP2A.
MP2A phosphorylation in the EBV1LMP2A tyrosine
oint mutant LCLs
Previously, it has been shown that the mutation of
yrosine 112 within the LMP2A amino-terminal domain
revents the phosphorylation of LMP2A (Fruehling et
l., 1998). To determine whether tyrosines at position
0, 64, or 101 had an effect on LMP2A phosphor-
lation, cellular lysates from EBV1LMP2AY60F,
BV1LMP2AY64F, and EBV1LM2AY101F were used in
mmunoprecipitations with an LMP2A-specific anti-
ody (Fig. 4). To test for LMP2A phosphorylation,
MP2A immunoprecipitations were divided equally
nd immunoblotted with an anti-phosphotyrosine an-
ibody [APT (PY20-HRP)] (Fig. 4A) or immunoblotted
ith an LMP2A antibody (Fig. 4B). LMP2A was not
etected in the EBV1LMP2A2 LCL included as a
egative control. In Fig. 4A, LMP2A was constitutively
hosphorylated in the control EBV1LMP2A1 LCL
ane, as previously described (Miller et al., 1995).
MP2A was phosphorylated in the Y60F, Y64F, and
al domain. (A) The amino acid sequence of the LMP2A amino-terminal
f each LMP2A tyrosine on in vitro function is also depicted. Tyrosines
as tyrosines 60, 64, and 101 (this study) for LMP2A in vitro function.
r, 1997; Fruehling et al., 1998). Upon phosphorylation, tyrosines 74 and
e Lyn PTK (Fruehling et al., 1998). (B) To investigate the role of tyrosines
ylalanine. A restriction site was incorporated adjacent to the mutation
estriction site addition was silent in regard to the LMP2A amino acid-termin
ance o
as well
gnecke
inds th
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488 SWART, FRUEHLING, AND LONGNECKERinor differences in the level of phosphorylation be-
ween each mutant and the EBV1LMP2A1 control,
hree LCLs containing each mutant were analyzed,
nd the differences were not reproducible. This vari-
tion is likely due to differences between cell lines
nd variation in experimental technique. Thus, ty-
osines 60, 64, and 101 are not important for the
onstitutive phosphorylation of LMP2A as observed in
FIG. 3. Immunofluorescence of EBV1LMP2A1, EBV1LMP2A2, and
right punctate staining localized to the cell membrane. EBV1LMP2AY
he same bright punctate fluorescence as in wild-type LCLs (D). EB
haracteristic LMP2A punctate staining. LCLs (1 3 106) were fixed to g
nti-LMP2A rat monoclonal antibodies (8C3). Fixed LCLs were then wa
nd photographed using a Zeiss Axioscope fluorescence microscope.BV-infected LCLs grown in culture. aCR-mediated protein tyrosine phosphorylation
emains blocked in EBV1LMP2A tyrosine point
utant LCLs
To determine the effect of each EBV1LMP2A tyrosine
utant on the induction of PTK activity, EBV1LMP2AY60F,
BV1LMP2AY64F, and EBV1LMP2AY101F LCLs were an-
lyzed for induction of tyrosine phosphorylation after BCR
A point mutant EBV-infected LCLs. EBV1LMP2A1 LCLs (D) depict a
, EBV1LMP2AY64F (B), and EBV1LMP2AY101F (C) LCLs demonstrate
P2A2 LCLs (E) show a dull background fluorescence without the
lides with acetone, blocked with 20% goat serum, and incubated with
nd incubated with anti-rat Cy3 secondary antibody. LCLs were viewedLMP2
60F (A)
V1LM
lass s
shed activation. The LCLs used in these experiments were
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489EPSTEIN–BARR VIRUS LMP2A TYROSINES 60, 64, AND 101atched for sIg expression by flow cytometry (data not
hown). The induction of tyrosine phosphorylation was
nalyzed at 2 and 5 min after BCR activation. A total of
our LCLs for each LMP2A point mutation were inves-
igated. Representative blots for EBV1LMP2AY60F,
BV1LMP2AY64F, EBV1LMP2AY101F, EBV1LMP2A2,
nd EBV1LMP2A1 LCLs are shown in Fig. 5. In the
BV1LMP2A1 LCL, included as a positive control, several
roteins are constitutively phosphorylated in unstimulated
CLs (Fig. 5, lane 13), and this phosphorylation pattern
emains relatively unchanged on BCR activation (Fig. 5,
anes 14 and 15). In contrast, there is little constitutive
hosphorylation in unstimulated cellular lysates from
FIG. 4. LMP2A is phosphorylated in EBV1LMP2A tyrosine point
utant LCLs. Representative EBV1LMP2A1, LMP2AY60F, LMP2AY64F,
nd LMP2AY101F LCLs were immunoprecipitated for LMP2A followed
y immunoblotting with anti-phosphotyrosine (APT) (A) or anti-LMP2A
B) antibodies. (A) LMP2A shows constitutive phosphorylation in the
ontrol EBV1LMP2A1 LCL lane. In the Y60F, Y64F, and Y101F LCL
anes, LMP2A depicts the same constitutive phosphorylation as the
ositive control. Phosphorylated LMP2A was not detected in the
BV1LMP2A2 lane (B) The amount of LMP2A immunoprecipitated
rom each LCL were similar. No LMP2A was detected in the
BV1LMP2A2 LCL included as a negative control. LCLs (2 3 107)
ere resuspended and equilibrated in serum-free RPMI. Cells were
mmediately lysed with 1% Triton X-100 lysis buffer, and the insoluble
ysates were cleared by centrifugation. Cleared lysates were then
ncubated with LMP2A monoclonal antibody; immune complexes were
aptured on protein G–Sepharose and washed four times with lysis
uffer. Immunoprecipitated proteins were resuspended in 23 SDS
ample buffer and then equally divided on 9% SDS–PAGE for separa-
ion by electrophoresis. The separated proteins were transferred to
mmobilon and blocked in 4% milk (LMP2A blot) or 3% BSA (APT blot).
A) APT immunoblots were incubated with HRP-linked antiphosphoty-
osine antibody (PY20-HRP) and washed with TBST. (B) LMP2A immu-
oblots were incubated with biotinylated-LMP2A antibody, washed with
BST, and incubated with NeutrAvidin-HRP antibody. Proteins were
etected by ECL. Protein standards are indicated at the left in kilodal-
ons.BV1LMP2A2 LCLs (Fig. 5, lane 10); however, upon acti- dation of the BCR, the number of phosphorylated proteins
ncreased substantially, as previously described (Fig. 5,
anes 11 and 12) (Miller et al., 1995). The EBV-infected
MP2AY60F, LMP2AY64F, and LMP2AY101F LCLs showed
number of constitutively phosphorylated proteins before
CR activation (Fig. 5, lanes 1, 4, and 7), and there was little
hange in the protein tyrosine phosphorylation pattern after
CR activation, similar to the EBV1LMP2A1 LCL (Fig. 5,
anes 2, 3, 5, 6, 8, and 9). In addition, the constitutively
hosphorylated protein LMP2A (54 kDa) was present, and
ts phosphorylation state was unchanged upon stimulation
f the BCR in all LMP2A1 LCLs as previously described
Fruehling et al., 1996, 1998; Fruehling and Longnecker,
997). The observed subtle differences between the
BV1LMP2A1 LCLs and the tyrosine point mutations,
uch as the phosphorylation of LMP2A, were not signifi-
ant. Multiple cell lines were tested. Minor differences were
bserved that could be accounted for by cell line variability,
ut subtle effects by the specific mutants on certain ty-
osine phosphorylated proteins cannot be excluded.
alcium mobilization in EBV1LMP2A1 and
BV1LMP2A point mutant LCLs after BCR activation
To assess the effect of LMP2A tyrosine point muta-
ions on calcium mobilization, multiple EBV1LMP2A1,
BV1LMP2A2, EBV1LMP2AY60F, EBV1LMP2AY64F,
nd EBV1LMP2AY101F LCLs were loaded with the cal-
ium indicator dye Fluo-3 (fluo-3-acetoxymethyl ester)
nd monitored for fluorescence after BCR activation.
verage values were calculated for the number of exper-
ments indicated in the table for each LCL. All tyrosine
oint mutant and wild-type control LCLs were derived
n parallel and matched for BCR expression by flow
ytometry (data not shown). Previously described
BV1LMP2A2 (ES1, ES5, and ES6) and EBV1LMP2A1
LCL1 and LCL2) LCLs were used as controls (Table 1)
Miller et al., 1994). EBV1LMP2A1 LCLs demonstrated a
inimal calcium flux response (Table 1, 2–34%) com-
ared with the range of calcium mobilization observed in
he EBV1LMP2A2 LCLs (Table 1, 123–313%). Represen-
ative LMP2A tyrosine point mutant LCLs also had a
inimal calcium flux of 4–33% (LMP2AY60F), 2–8%
LMP2AY64F), and 6–17% (LMP2AY101F), which was sim-
lar to that for EBV1LMP2A1 LCLs (Table 1, 2–34%).
herefore, tyrosines located at positions 60, 64, and 101,
ithin the LMP2A amino-terminal domain, are not re-
uired for the LMP2A-mediated block on calcium mobi-
ization after BCR activation.
nduction of BZLF1 expression in LMP2A tyrosine
oint mutant LCLs after BCR activation
To investigate the activation of lytic replication
n EBV1LMP2AY60F, EBV1LMP2AY64F, and EBV1
MP2AY101F LCLs, the expression of BZLF1, the imme-
iate-early transactivator of EBV lytic replication, was
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490 SWART, FRUEHLING, AND LONGNECKERnalyzed after BCR activation. LCLs were either un-
reated (2) or BCR cross-linked (1), cultured for 48 h,
nd then analyzed for BZLF1 expression by immunoblot-
ing with BZ1 monoclonal antibody (Young et al., 1989). A
otal of four EBV1LMP2AY60F, three EBV1LMP2AY64F,
nd four EBV1LMP2AY101F LCLs were tested. Repre-
entative data shown in Fig. 6 indicate that BZLF1 ex-
ression occurs in EBV1LMP2A2 LCLs after BCR acti-
ation (Fig. 6, lane 8). In contrast, EBV1LMP2A1 LCLs
o not express BZLF1 after BCR activation, as previously
escribed (Fig. 6, lane 10) (Miller et al., 1994). As in the
BV1LMP2A1 LCL, there is no induction of BZLF ex-
ression in LMP2AY60F, LMP2AY64F, and LMP2AY101F
CLs on BCR activation (Fig. 6, lanes 2, 4, and 6). Thus
yrosines 60, 64, and 101 are not required for LMP2A to
ediate the inhibition of nuclear gene transcription after
CR activation.
DISCUSSION
In this study, the role of LMP2A tyrosines 60, 64, and
01 in LMP2A function in EBV-infected LCLs was ad-
ressed by the mutation of each tyrosine-to-phenylala-
ine. These tyrosines are strictly conserved in the
MP2A homologues from EBV-related g-herpesviruses,
hich infect Old World monkeys (Franken et al., 1995)
nd in EBV clinical isolates (Busson et al., 1995), which
uggests they may have an important role for LMP2A
unction. Tyrosines 60 and 101 are conserved in all EBV
linical isolates, whereas tyrosine 64 was changed to
spartic acid in approximately half of them. Mutational
nalysis has confirmed the importance of some of the
MP2A tyrosines. Mutation of tyrosines 74 or 85, the Syk
TK binding site of LMP2A (Fruehling and Longnecker,
FIG. 5. Protein tyrosine phosphorylation upon BCR cross-linking in
ncrease in tyrosine phosphorylated proteins upon activation of the BC
how no change in protein tyrosine phosphorylation between the 0-, 2-
3 3 107) were washed with serum-free media, equilibrated, and treat
entrifuged to remove insoluble material, and incubated with PY-20 ant
ith 1% Triton X-100 lysis buffer, resuspended in 23 SDS sample bu
lectrophoresed, transferred to Immobilon, blocked in 3% BSA, incuba
y ECL. Protein standards are illustrated at the left in kilodaltons.997), or tyrosine 112, the Lyn PTK binding site of LMP2A tFruehling et al., 1998), results in a fully nonfunctional
MP2A protein in EBV-infected LCLs grown in tissue
ulture. In addition, the deletion of amino acids 21–64 of
MP2A but not amino acids 21–36 of LMP2A resulted in
n LMP2A protein with only partial LMP2A function in
BV-infected LCLs grown in tissue culture (Fruehling et
l., 1996). Due to the conservation of tyrosines 60, 64,
nd 101, and the deletion mutational analysis suggesting
n important role for tyrosines 60 and 64 in EBV-infected
CLs grown in tissue culture, it was apparent that a
utational analysis of these tyrosines should be per-
ormed.
In the current study, analysis of EBV-transformed LCLs
nfected with a tyrosine-to-phenylalanine mutation at ty-
osine 60, 64, or 101 indicated that the expression, sub-
ellular localization, or phosphorylation of the protein
MP2A was unaffected by these mutations. In addition,
ormal BCR signal transduction was similarly blocked
hen compared to EBV1LMP2A1 LCLs as measured by
alcium mobilization, tyrosine phosphorylation, and the
nduction of lytic replication as monitored by BZLF1 ex-
ression. Although somewhat surprising, these studies
ndicate that tyrosines 60, 64, and 101 of LMP2A are not
equired for LMP2A function in vitro.
Previously, it has been suggested that specific SH2
omain-containing proteins may bind LMP2A upon phos-
horylation of the LMP2A tyrosines (Longnecker and
iller, 1996). Binding of a particular SH2 domain-contain-
ng protein would be dictated by the surrounding amino
cid sequences specific for its binding as previously
etermined by Cantley and colleagues (Cantley and
ongyang, 1994; Songyang and Cantley, 1995). A com-
arison of LMP2A tyrosine motifs in the LMP2A amino-
LMP2A tyrosine point mutant LCLs. EBV1LMP2A2 LCLs show an
or 5 min, whereas LMP2AY60F, LMP2AY64F, and LMP2AY101F LCLs
-min stimulation of the BCR, similar to the EBV1LMP2A1 LCLs. LCLs
anti-human Ig antibody for 0, 2, or 5 min. The cells were then lysed,
. Immune complexes were captured on protein A–Sepharose, washed
nd separated through 8% SDS–PAGE. The immune complexes were
PY20-HRP antibody, and washed with TBST. Proteins were detectedEBV1
R for 2
, and 5
ed with
ibodies
ffer, a
ted witherminus revealed homology to motifs that predict opti-
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491EPSTEIN–BARR VIRUS LMP2A TYROSINES 60, 64, AND 101al binding to a variety of known proteins involved in B
ell signal transduction. These motifs play an important
ole in the communication of the BCR with the Syk PTK
nd the Src family PTKs (Lyn, Fyn, Blk, and Lck) (for a
eview, see DeFranco, 1997). Recruitment of these PTKs
o the BCR yields activation of downstream signaling
ascades such as the phosphatidylinositiol pathway, the
hospholipase C-g pathway, and the Ras pathway (for a
eview, see Kurosaki, 1997). In previous studies, tyrosine
12 and the two tyrosines within the LMP2A ITAM (Y74
nd Y85) were shown to be essential for LMP2A in vitro
unction (Fruehling and Longnecker, 1997; Fruehling et
l., 1998). Tyrosine 112 was shown to bind the Lyn PTK,
hereas tyrosines 74 and 85 were shown to be essential
TABLE 1
Calcium Mobilization in EBV1LMP2A1, EBV1LMP2A2, and
Three LMP2A Point Mutations after BCR Cross-Linking
Cell line type and
namea No.b
Mean calcium increase
(%; range)c
BV1LMP2A2
ES1 7 123.0 (54–262)
ES5 6 313.0 (132–875)
ES6 3 159.0 (149–164)
BV1LMP2A1
LCL1 8 2.0 (0–7)
LCL2 9 7.0 (0–16)
AB3WT 3 8.0 (7–10)
AE8WT 3 9.0 (0–13)
A10WT 4 34.0 (15–56)
C12WT 4 8.0 (3–16)
12WT 2 4.0 (4)
BV1LMP2AY60F
AA6m 3 4.0 (1–4)
AD5m 3 18.0 (12–29)
AD7m 3 33.0 (2–86)
AH7m 4 5.0 (3–8)
BV1LMP2AY64F
A4m 2 9.0 (7–14)
A9m 2 2.0 (0–5)
C2m 3 5.0 (2–6)
E7m 2 8.0 (5–10)
BV1LMP2AY101F
5m 3 6.0 (4–7)
11m 3 10.0 (5–13)
15m 3 13.0 (5–18)
14m 3 17.0 (15–18)
Note. LCLs (3 3 106) were resuspended in loading buffer and loaded
ith 2 mM Fluo-3. Cells were then washed twice and resuspended in
oading buffer. Loaded cells were BCR stimulated using anti-human Ig
ntibody and measured for fluorescence with a Perkin–Elmer LS-5B
pectrofluorimeter.
a EBV1LMP2A2 (ES1, ES5, and ES6) and EBV1LMP2A1 (LCL1 and
CL2) LCLs were previously described. All other LCLs were produced
ccording to this study.
b Number of times calcium mobilization was determined for each
CL.
c Mean percent calcium concentrations calculated for each LCL.or the binding of the Syk PTK to LMP2A. These results Eere in good agreement with the predicted specificities
f the Syk and Lyn SH2 domains. In regard to the specific
yrosines analyzed in the current study, the tyrosine 60
otif has the best homology for tyrosines that bind the
H2 domain of the adaptor proteins Crk or Nck (Song-
ang et al., 1993). Once recruited to LMP2A complexes,
hese adaptor molecules might recruit additional pro-
eins important in B cell signal transduction and function
f LMP2A in B-lymphocytes. The amino acid motif of
yrosine 64 is not predicted to bind any known SH2
omain. The tyrosine 101 motif contains an arginine at
he 13 position that is characteristic of the Csk SH2
referred motif (Songyang et al., 1994). Csk down-regu-
ates the activity of src family PTKs when they are re-
ruited to the BCR (Howell and Cooper, 1994). The inter-
ction of LMP2A with Csk would provide a convenient
odel for the LMP2A-mediated affect on Lyn activity
een in wild-type infected LCLs. From the current study,
t is apparent that none of these proposed interactions
re important for LMP2A function in vitro.
Previous studies had indicated a potentially important
unctional role for tyrosines 60 and 64 of LMP2A; the
eletion of amino acids 21–64 but not amino acids 21–36
esulted in an LMP2A protein with only partial function in
BV-transformed LCLs grown in vitro (Fruehling et al.,
996). In particular, there was little constitutive phosphor-
lation of cellular proteins in the 21–64 deletion mutant
ompared with wild-type infected cells in the absence of
CR activation. In addition, LMP2A was only phosphor-
lated after BCR activation in contrast to wild-type in-
ected LCLs, in which LMP2A is highly, constitutively
yrosine phosphorylated. Finally, calcium mobilization
as blocked as in wild-type infected LCLs, whereas lytic
FIG. 6. BZLF expression in LMP2AY60F, LMP2AY64F, and
MP2AY101F EBV-infected LCLs after BCR activation. BZLF expression
as induced after anti-BCR treatment in EBV1LMP2A2 LCLs (lane 8).
owever, BZLF expression was not induced after anti-BCR treatment in
BV-infected LMP2AY60F, LMP2AY64F, and LMP2AY101F LCLs (lanes
, 4, and 6), similar to the results shown by the control EBV1LMP2A1
CL (lane 10). Before BCR activation, BZLF expression was not de-
ected in any of the LCLs (lanes 1, 3, 5, 7, and 9). LCLs (4 3 106) were
reated (1) or not treated (2) with anti-BCR antibodies for 48 h.
hole-cell lysates were separated by 8% SDS–PAGE, transferred to
mmobilon, immunoblotted with BZ1 monoclonal antibody, incubated
ith anti-mouse Ig-HRP-linked secondary antibody, and detected by
CL. Protein standards are indicated at the left in kilodaltons.
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492 SWART, FRUEHLING, AND LONGNECKERiral replication was readily induced after BCR activation,
imilar to LMP2A null infected LCLs. Because mutation
f tyrosines 60 and 64 resulted in none of the phenotypes
ssociated with the 21–64 deletion mutant, it is apparent
hat other LMP2A sequences within the deletion must be
onsidered. Two proline-rich sequences were deleted:
ne a potential binding site for SH3 domains, and the
ther a PY motif that may be important for the binding of
roteins containing a WW domain.
Summarization of the in vitro studies using site-spe-
ific mutation of the eight tyrosines in the amino-terminal
omain of LMP2A indicates tyrosines 23 and 31 are
onessential for LMP2A function in vitro, both of which
ere deleted in the 21–36 deletion mutant of LMP2A
ithout affecting LMP2A in vitro function (Fruehling et al.,
996). Tyrosines 60, 64, and 101 were also shown to be
onessential for in vitro LMP2A function in the current
tudy. The importance of tyrosines 74, 85, and 112 in
inding cellular PTKs was previously shown to be es-
ential for LMP2A in vitro function (Fruehling and Long-
ecker, 1997; Fruehling et al., 1998). Although tyrosines
3, 31, 60, 64, and 101 are not necessary for the LMP2A-
ediated block on BCR activation of protein tyrosine
hosphorylation, calcium mobilization, and lytic replica-
ion, these tyrosines may be important in other LMP2A
unctions related to the persistence of EBV in the human
ost. A recent in vivo study using LMP2A transgenic
ice indicates that LMP2A provides both a B cell devel-
pment and survival signal (Caldwell et al., 1998). Stud-
es using a similar transgenic approach with these same
utations may reveal that these tyrosines are necessary
or some aspect of promoting B cell development and/or
urvival in vivo.
The ability of LMP2A to both block BCR signaling in
itro and promote B cell development and survival in vivo
llustrates the many functions viral proteins can have
epending on the system being used to study protein
unction. Future studies, which delineate the mechanism
y which LMP2A is able to mediate seemingly opposite
ffects on normal B cell biology, will help define the
trategy EBV has evolved to persist in the human host.
MATERIALS AND METHODS
ell lines and cultures
LCLs were cultured in RPMI 1640 (GIBCO) supple-
ented with inactivated FBS (10%) and 0.1% penicillin/
treptomycin (GIBCO) (complete media). B95-8 is an
BV-infected marmoset cell line that is partially permis-
ive for viral replication (Miller and Lipman, 1973; Miller
t al., 1972). P3HR1 (clone 13), an EBV-infected Burkitt’s
ymphoma cell line (a gift from George Miller), has one
ype of EBV genome in which the DNA segment encod-
ng EBNA2 and the last two exons of EBNA-LP are
eleted (Heston et al., 1982). LCL1, LCL2, and LCL10 are
BV1LMP2A1 LCLs, and ES1, ES5, and ES6 are EBV1LMP2A2 LCLs (Miller et al., 1994). Primary human
eripheral B-lymphocytes were obtained from blood
amples of healthy donors through centrifugation over a
icoll-Plaque layer (Pharmacia). For EBV1 donors, T-
ymphocytes were removed as previously described
Marchini et al., 1991).
ntibodies
Whole goat anti-human Ig used in surface BCR acti-
ation experiments was purchased from Southern Bio-
echnological Associates (Birmingham, AL), and goat -
nti-human F(ab9)2 was purchased from Jackson Immu-
oResearch Laboratories (West Grove, PA). The rat anti-
uman monoclonal LMP2A unconjugated and biotinyl-
ted antibodies have been previously described (Frueh-
ing et al., 1996). The donkey anti-rat Cy3 secondary
ntibody was purchased from Jackson ImmunoResearch
aboratories. The mouse monoclonal antibody to the
ZLF1 protein (BZ1) has been previously described
Young et al., 1989) and kindly provided by Lawrence
oung. The anti-phosphotyrosine unconjugated (PY20)
nd horseradish peroxidase (HRP)-conjugated (PY20-
RP) antibodies were purchased from Santa Cruz Bio-
echnology (Santa Cruz, CA). All other HRP-linked sec-
ndary antibodies were obtained from Amersham
Arlington Heights, IL). The NeutrAvidin-HRP was pur-
hased from Pierce (Rockford, IL).
onstruction of plasmids
The genomic LMP2AY60F, LMP2AY64F, and LMP2AY101F
utations were produced using a PCR-based strategy as
escribed previously (Fruehling et al., 1996). In addition
o the point mutations, unique restriction enzyme sites
stBI, BstEII, and PmlI were generated adjacent to the
espective tyrosine codon. The recombinant LMP2A frag-
ents containing both the tyrosine mutation and the
nique restriction enzyme site were incorporated into
RH6, which contains a KpnI–EcoRI fragment from B95-8
BV DNA. All recombinant LMP2A mutants were se-
uenced for the presence or absence of the desired
yrosine-to-phenylalanine point mutation. pSVNaeZ,
hich was used to induce EBV replication, and EcoRI-A,
hich was used to rescue the EBNA2 and EBNA-LP
eletion within the P3HR1 cell line, have been described
Marchini et al., 1991; Swaminathan et al., 1991).
eneration of LMP2AY60F, LMP2AY64F, and
MP2AY101F LCLs
Recombinant LMP2A constructs were incorporated
nto virus using the transformation-incompetent, replica-
ion-competent EBV deletion mutant P3HR1. Recombi-
ant virus was produced by cotransfecting the P3HR1
clone 13) cell line with pSVNaeZ DNA to induce lytic
eplication, with EcoRI-A DNA to rescue the EBNA2 and
BNA-LP deletions in the P3HR1 genome, and with the
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493EPSTEIN–BARR VIRUS LMP2A TYROSINES 60, 64, AND 101ecombinant LMP2A DNA fragment (Longnecker et al.,
991). The recombinant virus was used to infect purified
eripheral B-lymphocytes as previously described
Fruehling and Longnecker, 1997). Clones emerged
ithin 4–6 weeks of the initial infection and plating. Each
lone was screened by PCR for incorporation of the
MP2AY60F, LMP2AY64F, or LMP2AY101F point muta-
ion.
erification of LMP2A tyrosine point mutations by
CR and Southern blotting
Genomic DNA from LCLs was prepared using protein-
se K and amplified in a 25-ml volume for 40 cycles.
rimers 59 LMP1 (CTAGGCGCACCTGGAGGTGG) and 39
MP1 (AGTCAGTCAGGCAAGCCTAT) were used to
creen LCLs containing an 81-bp smaller LMP1 gene
resent within the EBV genome, in which LMP2A point
utations were incorporated. LMP1 and LMP2A genes
re adjacent within the EBV genome. Ethidium bromide-
tained PCR products were viewed after electrophoresis
hrough 1.5% NuSieve 3:1 agarose (FMC Bioproducts,
ockland, ME) to determine the size of amplified prod-
cts. In addition, genomic DNA from a representative
roup of LMP2AY60F, LMP2AY64F, and LMP2AY101F
CLs were PCR amplified using specific LMP2A primers
p20 (CTGCTGCAGCTATGGGGTCC) and Eco47III (CAC-
AGCCAGCGACTGATCCG)]. These PCR products were
eparated by electrophoresis, gel purified, ethanol pre-
ipitated, and sequenced to verify the presence of each
yrosine-to-phenylalanine point mutation.
PCR-identified LMP2AY60F, LMP2AY64F, and
MP2AY101F EBV-infected LCLs were further verified
y Southern blotting. Genomic DNA from EBV2,
BV1LMP2A1, EBV1LMP2A2, and EBV1LMP2A point
utant LCLs were prepared by cell lysis, proteinase K
reatment, phenol extraction, and ethanol precipitation.
he DNA was then digested with restriction enzymes
orrelating with the unique restriction site incorporated
nto each EBV1LMP2A recombinant tyrosine point mu-
ant. Digested DNAs were separated by electrophoresis
n a 1% agarose gel, transferred to a nylon membrane
GeneScreen; NEN Bio Life Science Products, Boston,
A), and probed with a 32P-labeled 1872-bp fragment
enerated from a BglI digest of RH6 (Longnecker et al.,
992).
The verified LMP2AY60F, LMP2AY64F, LMP2AY101F,
BV1LMP2A2, and EBV1LMP2A1 control LCLs were
haracterized for surface BCR expression by flow cytom-
try using a goat anti-human fluorescein-conjugated Ig
ntibody diluted at 1:50 (Southern Biotechnology Asso-
iates) as previously described (Miller et al., 1993).
mmunofluorescence
LCLs were fixed to glass slides with acetone at 220°C
or 5 min, blocked with 20% goat serum (GIBCO) for 10 min at room temperature, and incubated with anti-
MP2A rat monoclonal antibodies diluted 1:1000 in 20%
oat serum. Fixed LCLs were then washed again with
0% goat serum for 10 min at room temperature and
ncubated with a goat anti-rat secondary antibody, Cy3,
iluted at 1:1000 for 30 min in the dark at room temper-
ture (Longnecker and Kieff, 1990). The slides were
ashed in PBS four or five times and viewed and pho-
ographed with a Zeiss Axioscope fluorescence micro-
cope.
timulation of LCLs and preparation of lysates
LCLs were resuspended in serum-free media and
quilibrated for 15 min at 37°C. (The number of cells
sed is indicated in each figure legend.) The LCLs were
hen stimulated with 25 mg/ml of goat anti-human Ig
ntibody (Southern Biotechnology) for the times indi-
ated within the figure legend. Cells were lysed with 1%
riton X-100 lysis buffer (1% Triton X-100, 50 mM Tris–HCl
pH 7.4), 150 mM NaCl, 2 mM EDTA, 10 mg/ml each of
epstatin and leupeptin, 0.5 mM phenylmethylsulfonyl
luoride, 1 mM sodium orthovanadate, and 10 mM so-
ium fluoride). The insoluble material was removed by
entrifugation at 4°C.
For Western blots, 23 SDS sample buffer was imme-
iately added to the lysed cells, heated at 70°C for 5–10
in, and loaded into SDS–PAGE for separation.
mmunoprecipitations and immunoblotting
Cleared lysates were incubated with the appropriate
ntisera for 1 h at 4°C. The immune complexes were
aptured with either protein A– or G–Sepharose (Phar-
acia) for 1 h at 4°C and washed four times with 1%
riton X-100 lysis buffer. Immunoprecipitated proteins
ere then resuspended in 23 SDS sample buffer,
eated at 70°C for 5–10 min, and separated on SDS–
AGE (percentage of gels is indicated within the figure
egends).
For immunoblotting, immune complexes or whole-cell
ysates were electrophoresed and transferred to Immo-
ilon (Millipore). Membranes were blocked in milk or
SA, as indicated in the figure legends, for 1 h at room
emperature and incubated in primary antibody diluted in
ris-buffered saline–Tween (TBST) for 1 h at room tem-
erature. The membranes were then washed three times
n TBST and incubated with an HRP-linked secondary
ntibody for 30 min at room temperature. Membranes
ere then washed four times in TBST, and the proteins
ere detected by enhanced chemiluminescence (ECL;
ierce).
alcium mobilization
LCLs (3 3 106) were resuspended in loading buffer
145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 10M HEPES, 10 mM glucose, probenicid, and 1% BSA)
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494 SWART, FRUEHLING, AND LONGNECKERnd loaded with 2 mM calcium binding dye Fluo-3 (Mo-
ecular Probes, Eugene, OR) for 30 min at room temper-
ture. After loading, the cells were washed twice and
esuspended in loading buffer. The loaded cells were
hen measured for fluorescence before and after BCR
ross-linking with goat anti-human Ig antibody in a Per-
in–Elmer LS-5B luminescence spectrometer (Norwalk,
T). Excitation and emission values for fluo-3 are 505
nd 530 nm, respectively. Auto F [or Fmin (minimal fluo-
escence)] was determined for each LCL by performing
he above procedure without fluo-3. Baseline fluores-
ence (F) was recorded for 1 min, and maximum fluores-
ence (Fmax) was measured by the addition of 40 mM
igitonin. Calcium concentration was calculated accord-
ng to the formula [Ca21] 5 400 (F 2 Fmin)/(Fmax 2 F).
nduction of EBV lytic replication
LCLs (4 3 106) were treated with 100 mg/ml goat
nti-human Ig F(ab9)2 antibody (Jackson ImmunoRe-
earch Laboratories) or left untreated for 48 h at 37°C.
fter incubation, cells were washed with PBS, and
hole-cell lysates were prepared. Lysates were then
eparated by electrophoresis through 8% SDS–PAGE,
ransferred to Immobilon, blocked in 5% milk for 1 h at
oom temperature, and incubated with mouse monoclo-
al antibody, BZ1, for 1 h at room temperature. The
embrane was then washed in TBST, incubated with
econdary anti-mouse-HRP-linked antibody for 30 min at
oom temperature, washed again with TBST, and de-
ected by ECL (Pierce).
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